James Alexander Booth
United Kingdom
8m
Hello to copiers and followers, Recent tariffs have underscored that the United States is less attractive for investment. The U.S. economy accounts for roughly 20% of global GDP, yet its stock market represents 63% of the total value of global stock markets. Record-high U.S. public exposure to domestic equities signals overvaluation and concentrated investor portfolios. While American companies lead in innovation, Chinese firms are now formidable competitors, surpassing U.S. counterparts in electric vehicles (EVs), solar energy, 5G, AI applications, and advanced manufacturing. China's innovation pace is remarkable, yet its companies trade at significantly lower valuations than U.S. peers. International and Chinese retail investors have minimal exposure to Chinese stocks, resulting in some of the world's lowest valuations for companies with cutting-edge technology. Despite risks, the Chinese stock market's charts, valuations, and investor positioning indicate the early stages of a potential multi-year bull market, akin to the U.S. market's performance over the past decade. Upcoming U.S.-China tariff negotiations are likely to be tense, with leaders posturing for domestic audiences. However, mutual economic interests suggest a deal will eventually emerge, likely after significant drama. This environment presents a compelling opportunity for investment in undervalued Chinese equities with strong growth potential. I have balanced this exposure with exposure to world leading pharmaceutical companies that have excellent growth prospects based upon an aging population and outstanding drug pipelines. I expect the next few months to be volatile, but the recent volatility will have helped clear markets ready for a move higher. I also expect the Chinese to launch a stimulus package that will be beneficial to stocks. Regards, Jim
1 reply
null
.